GABAvsMagnesium Glycinate

GABA binds to GABA-A receptors (ligand-gated Cl- channels with alpha1-6, beta1-3, gamma1-3 subunits) and GABA-B receptors (G-protein coupled, Gi/o mediated), reducing neuronal excitability through hyperpolarization. However, supplemental GABA has limited blood-brain barrier penetration due to absence of a dedicated transporter and rapid metabolism by GABA-transaminase and succinate semialdehyde dehydrogenase in periphery. The calming effects may be mediated through: (1) GABA-A and GABA-B receptors in the enteric nervous system (gut-brain axis) — vagal afferents project to the nucleus tractus solitarius and influence limbic regions; (2) small amounts crossing the BBB via paracellular leakage or in individuals with compromised barrier integrity; (3) peripheral effects reducing systemic stress markers (cortisol, heart rate variability). PharmaGABA (Lactobacillus fermentation product) may have better absorption via peptide-like transport or different pharmacokinetics.

Magnesium is required for over 300 enzymatic reactions including neurotransmitter synthesis (tyrosine hydroxylase, tryptophan hydroxylase), energy production (ATPases, kinases, glycolytic enzymes), and DNA repair (PARP, DNA polymerases). In the brain, magnesium blocks NMDA receptors at the voltage-dependent Mg2+ binding site within the channel pore (GluN1/GluN2 subunits), preventing excessive calcium influx and excitotoxicity — Mg2+ is displaced only upon depolarization and glycine/glutamate binding. The glycine component activates inhibitory glycine receptors (GlyR alpha1/alpha2) in the brainstem and spinal cord, and serves as an obligatory co-agonist at the GluN1 glycine site of NMDA receptors. Glycine also modulates NMDA receptor function. Together, magnesium and glycine produce calming effects through complementary inhibitory mechanisms: reduced glutamatergic excitability and enhanced inhibitory neurotransmission.